iCIP™

iCIP™

The combination of LiPlaCis® and DRP®—together known as iCIP™—enables the identification of patients most likely to benefit from LiPlaCis® treatment, while reducing exposure to the side effects of cisplatin. Cisplatin is used by 10-20% of cancer patients but is only effective in about 25% of cases, and many experience significant side effects.

LiPlaCis® improves upon traditional cisplatin by using a specialized liposome carrier that releases the drug directly at the tumor site, increasing its effectiveness and lowering toxicity. In tandem, DRP® serves as a predictive tool, assessing a patient’s suitability for cisplatin based on gene expression from 205 genes linked to drug sensitivity and resistance.

Together, iCIP™ ensures that patients likely to benefit are treated with LiPlaCis®, while DRP® minimizes unnecessary treatment for those unlikely to respond. Phase 2b clinical trials confirm this approach's success: patients selected via DRP® showed better treatment responses, longer progression-free survival, and potentially extended overall survival compared to those with low DRP scores.

This marks a significant breakthrough in precision oncology, underscoring iCIP™'s role in offering a more personalized, effective, and safer cancer treatment solution, reflecting CHOSA’s commitment to advancing cancer care through innovation.